Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Esomeprazole on BI 1819479 PK in Healthy Males
NCT05467475Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI1819479 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) up to 31 days and Maximum measured concentration of the analyte in plasma (Cmax) up to 31 days. Started Oct 2022; status: completed.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05467475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467475.